Search research articles
Contact Us
Filters
Showing results (131-140 of 251) with videos related to
Page
of 26
Sort By:
ESMO Open
|
August 27, 2022
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF<sup>wt</sup> metastatic colorectal cancer
J Tabernero, A Grothey, D Arnold, et al.
ESMO Open
|
March 12, 2024
Impact of KRAS<sup>G12</sup> mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial
J Tabernero, J Taieb, M Fakih, et al.
British Journal of Cancer
|
August 2, 2006
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma
S Falk, A Anthoney, M Eatock, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2001
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET)
P Flamen, O S Hoekstra, F Homans, et al.
ESMO Open
|
April 5, 2023
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
C J A Punt, V Heinemann, T Maughan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 16, 2013
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
S Kubicka, R Greil, T André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2009
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
E Van Cutsem, F Rivera, S Berry, et al.
Acta Gastro-Enterologica Belgica
|
July 15, 2005
Report on the Belgian consensus meeting on colorectal cancer screening
M Adler, M De Vos, A Dufour, et al.
Lancet (London, England)
|
November 10, 1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
P Rougier, E Van Cutsem, E Bajetta, et al.
AIDS and Behavior
|
September 17, 2024
Profile of Persons Recently Infected with HIV-1 in Belgium: New Insights to Tailor Prevention Efforts
C Vanden Bulcke, J Deblonde, C Necsoi, et al.
Page
of 26
Search research articles
Search
Showing results (131-140 of 251) with videos related to
Sort By:
Page
of 26
ESMO Open
|
August 27, 2022
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF<sup>wt</sup> metastatic colorectal cancer
J Tabernero, A Grothey, D Arnold, et al.
ESMO Open
|
March 12, 2024
Impact of KRAS<sup>G12</sup> mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial
J Tabernero, J Taieb, M Fakih, et al.
British Journal of Cancer
|
August 2, 2006
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma
S Falk, A Anthoney, M Eatock, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2001
Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET)
P Flamen, O S Hoekstra, F Homans, et al.
ESMO Open
|
April 5, 2023
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
C J A Punt, V Heinemann, T Maughan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 16, 2013
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
S Kubicka, R Greil, T André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2009
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
E Van Cutsem, F Rivera, S Berry, et al.
Acta Gastro-Enterologica Belgica
|
July 15, 2005
Report on the Belgian consensus meeting on colorectal cancer screening
M Adler, M De Vos, A Dufour, et al.
Lancet (London, England)
|
November 10, 1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
P Rougier, E Van Cutsem, E Bajetta, et al.
AIDS and Behavior
|
September 17, 2024
Profile of Persons Recently Infected with HIV-1 in Belgium: New Insights to Tailor Prevention Efforts
C Vanden Bulcke, J Deblonde, C Necsoi, et al.
Page
of 26